Researchers shed light on how the Notch pathway can suppress the formation of some types of brain cancer tumors.
A new study discovers molecular pathways that could lead to new targeted therapies which may potentially treat Glioblastoma, the most common and lethal form of brain cancer in adults.
Researchers at the Stanford University School of Medicine and Lucile Packard Children’s Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less toxic, better targeted treatment approaches over the next two years, the researchers said.
A new study reports changes in immune function can occur up to five years before the diagnosis of brain cancer, which typically only produces symptoms three months before it is detected.
Discovery could pave the way to developing new treatments to target glioblastoma brain cancer.
A new vaccine for glioblastoma brain cancer suspends tumor growth and is well tolerated by patients, according to the results of an early phase clinical trial.
PTEN deficiency drives an increased expression of LOX. LOX attracts macrophages which protect gliobastoma brain cancer cells and provide growth factor support for the tumor, a new mouse study reveals.
Researchers discover key elements associated with tumor cells binding to blood vessels. The findings could help develop new treatments to halt the development of brain tumors.
Understanding glioblastoma at the genetic, molecular level Glioblastoma is the most common and most lethal form of brain tumor in...
DIPG cancer cells exposed to MI-2 fail to maintain healthy levels of cholesterol and die quickly, by inhibiting lanosterol synthase. Additionally, while MI-2 destroys glioma cancer cells, the drug does not damage healthy brain cells.
A new study could pave the way for more effective treatment of infantile ETMR/ETANTR brain cancer.
Researchers uncover a possible reason as to why astrocytomas don't respond to standard forms of cancer treatment.
